Non-Viral Drug Delivery Systems Global Market Report 2025
상품코드:1769681
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
비바이러스 약물 전달 시스템 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간 동안의 성장은 표적 치료의 채택 증가, 약물 전달 혁신에 대한 투자 확대, 비침습적 치료 방법에 대한 관심 증가, 인공 지능의 통합 강화, 지속 방출 의약품 제형에 대한 필요성 증가에 의해 촉진될 것입니다. 이 기간 동안 예상되는 주요 동향으로는 나노 캐리어 기술의 발전, 차세대 생체 재료의 개발, mRNA 전달 시스템의 혁신, 스마트 약물 전달 장치의 통합, 유전자 편집 전달 기술의 개선 등이 있습니다.
맞춤형 의약품에 대한 수요가 증가함에 따라 비바이러스 약물 전달 시스템 시장이 성장할 것으로 예상됩니다. 맞춤형 의약품은 개인의 유전적 특성, 생활 방식 및 환경적 요인에 맞춤화된 치료 방법입니다. 이러한 수요 증가는 각 환자의 질병의 근본 원인을 해결하는 보다 효과적인 치료법의 잠재력에 의해 촉진되고 있습니다. 비바이러스 시스템은 약물이나 유전자를 세포에 안전하게 전달하여 위험을 최소화하고 치료의 정확성을 높임으로써 맞춤형 의약품을 지원합니다. 예를 들어, 2024년 2월, 미국에 본사를 둔 비영리 단체인 Personalized Medicine Coalition은 FDA가 2023년에 희귀 질환 환자를 위한 16개의 새로운 맞춤형 치료법을 승인했다고 밝혔습니다. 이는 2022년에 승인된 6개보다 증가한 수치입니다. 그 결과, 맞춤형 의약품에 대한 선호도가 높아지면서 비바이러스 약물 전달 시스템 시장이 확대되고 있습니다.
비바이러스 약물 전달 시스템 시장의 주요 기업들은 RNA 기반 치료법의 개발 및 전달을 촉진하기 위해 사전 최적화된 이온화 지질 혼합 시스템과 같은 첨단 기술의 사용을 강조하고 있습니다. 이 제형 기술을 통해 RNA 분자를 지질 나노 입자 내에 효율적으로 캡슐화하여 안정성, 유효 성분 보호 및 표적 유전자 전달을 보장할 수 있습니다. 예를 들어, 2024년 9월, 미국에 본사를 둔 생명공학 기업인 Cytiva는 자사의 NanoAssemblr Ignite 및 Ignite+ 플랫폼과 호환되는 RNA 전달 LNP 키트를 출시했습니다. 이 시스템은 즉시 사용 가능한 이온화 지질 혼합물을 특징으로 하며, 신속한 RNA 유효 부하 스크리닝 및 전달 검증을 가능하게 하여, 특히 전염병 백신 개발에 유용합니다. 이 시스템은 자동화된 미세유체 플랫폼과 통합되고, GMP 등급 재료를 사용한 확장 가능한 제조를 지원하며, 발견부터 임상 시험에 이르기까지 사용자를 안내하는 프로토콜과 개념 증명 데이터를 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 비바이러스 약물 전달 시스템 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 비바이러스 약물 전달 시스템 시장 : 성장률 분석
세계의 비바이러스 약물 전달 시스템 시장 실적 : 규모와 성장(2019-2024년)
세계의 비바이러스 약물 전달 시스템 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 비바이러스 약물 전달 시스템 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 비바이러스 약물 전달 시스템 시장 : 전달 분자 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
생물학적 제제
소분자
세계의 비바이러스 약물 전달 시스템 시장 : 투여 생물학적 제제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
리보 핵산(RNA)
데옥시리보 핵산(DNA)
단백질 또는 펩티드
항체
세계의 비바이러스 약물 전달 시스템 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제약 및 생명 공학 기업
학술연구기관
계약 개발 제조 조직(CDMO)
병원 및 진료소
세계의 비바이러스 약물 전달 시스템 시장 : 생물학적 제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
펩티드
단백질
단일클론항체
RNA 기반 치료제
DNA 기반 치료법
세계의 비바이러스 약물 전달 시스템 시장 : 소분자 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
화학요법제
항염증제
항바이러스제
항생제
호르몬 약
제7장 지역별, 국가별 분석
세계의 비바이러스 약물 전달 시스템 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 비바이러스 약물 전달 시스템 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
비바이러스 약물 전달 시스템 시장 : 경쟁 구도
비바이러스 약물 전달 시스템 시장 : 기업 프로파일
Evonik Industries AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Cytiva : 개요, 제품 및 서비스, 전략 및 재무 분석
Arcturus Therapeutics Holdings Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
CureVac NV : 개요, 제품 및 서비스, 전략 및 재무 분석
PolyPid Ltd : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Ethris GmbH
Entos Pharmaceuticals Inc.
Liquidia Technologies Inc.
ReCode Therapeutics Inc.
Enable Injections Inc.
GenEdit Inc.
N4 Pharma Plc
Hopewell Therapeutics Inc.
Tiba Biotech LLC
Vesigen Therapeutics Inc.
Carmine Therapeutics Inc.
Evox Therapeutics Ltd
InnoCore Pharmaceuticals BV
Nanomerics Ltd
DelSiTech Ltd
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
비바이러스 약물 전달 시스템 시장(2029년) : 새로운 기회를 제공하는 국가
비바이러스 약물 전달 시스템 시장(2029년) : 새로운 기회를 제공하는 부문
비바이러스 약물 전달 시스템 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Non-viral drug delivery systems are methods used to administer therapeutic agents into the body without relying on viral vectors. These systems utilize various physical, chemical, or mechanical approaches-such as nanoparticles, liposomes, or polymer-based carriers-to effectively transport drugs to specific target areas. Their primary goal is to minimize the risks commonly associated with viral delivery methods, including immune responses and insertional mutagenesis. This strategy improves the overall efficacy of treatments while enhancing patient safety for a wide range of medical conditions.
Non-viral drug delivery systems are primarily used to deliver two main categories of molecules: biologics and small molecules. Biologics are therapeutic agents derived from living organisms and include proteins, peptides, monoclonal antibodies, as well as nucleic acid-based treatments like RNA and DNA. The biologics delivered using these systems include ribonucleic acid (RNA), deoxyribonucleic acid (DNA), proteins or peptides, and antibodies. The major end users of these systems are pharmaceutical and biotechnology companies, academic and research institutions, contract development and manufacturing organizations (CDMOs), and hospitals and clinics.
The non-viral drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides non-viral drug delivery systems market statistics, including the non-viral drug delivery systems industry global market size, regional shares, competitors with the non-viral drug delivery systems market share, detailed non-viral drug delivery systems market segments, market trends, and opportunities, and any further data you may need to thrive in the non-viral drug delivery systems industry. This non-viral drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The non-viral drug delivery systems market size has grown rapidly in recent years. It will grow from $8.60 billion in 2024 to $9.84 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth during the historical period is due to various drivers such as the increasing demand for safer gene therapy options, advancements in nanotechnology, a higher prevalence of chronic diseases, a stronger focus on personalized medicine, and enhanced regulatory backing for non-viral platforms.
The non-viral drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $16.72 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. Growth in the forecast period will be driven by the increasing adoption of targeted therapies, greater investment in drug delivery innovation, rising interest in non-invasive treatment methods, enhanced integration of artificial intelligence, and the growing need for sustained-release drug formulations. Key trends anticipated during this period include progress in nanocarrier technologies, development of next-generation biomaterials, innovations in mRNA delivery systems, incorporation of smart drug delivery devices, and improvements in gene editing delivery techniques.
The rising demand for personalized medicines is anticipated to drive the growth of the non-viral drug delivery systems market. Personalized medicine is a treatment approach tailored to an individual's genetic profile, lifestyle, and environmental factors. This growing demand is fueled by the potential for more effective treatments that address the root causes of disease in each patient. Non-viral systems support personalized medicine by delivering drugs or genes safely to cells, thereby minimizing risks and enhancing treatment accuracy. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, up from six approvals in 2022. As a result, the increasing preference for personalized medicines is contributing to the expansion of the non-viral drug delivery systems market.
Key companies in the non-viral drug delivery system market are emphasizing the use of advanced technologies, such as pre-optimized ionizable lipid mix systems, to facilitate the development and delivery of RNA-based therapies. This formulation technology allows RNA molecules to be efficiently encapsulated within lipid nanoparticles, ensuring stability, payload protection, and targeted gene delivery. For instance, in September 2024, Cytiva, a U.S.-based biotechnology firm, introduced an RNA delivery LNP kit that is compatible with its NanoAssemblr Ignite and Ignite+ platforms. The system features a ready-to-use ionizable lipid mix that enables swift RNA payload screening and validation for delivery, particularly useful in vaccine development for infectious diseases. It integrates with automated microfluidic platforms, supports scalable manufacturing using GMP-grade materials, and provides protocols and proof-of-concept data to guide users from discovery through clinical trials.
In September 2023, SOHM Inc., a U.S.-based pharmaceutical firm, acquired ABBIE from CGA 369 for $10 million to enhance its non-viral gene-editing capabilities. This acquisition bolsters SOHM's ability to deliver large genetic payloads through integrase-based, non-viral platforms. ABBIE is being developed for off-the-shelf gene-editing kits, with plans for commercialization in 2024 and human trials expected by the end of 2025. CGA 369, also a U.S.-based biotechnology company, focuses on non-viral, integrase-driven gene-editing and genetic delivery solutions.
Major players in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, and Curapath Inc.
North America was the largest region in the non-viral drug delivery systems market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-viral drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the non-viral drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The non-viral drug delivery systems market consists of sales of exosomes, cell-penetrating peptides, and nanocrystals. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Non-Viral Drug Delivery Systems Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on non-viral drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for non-viral drug delivery systems ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-viral drug delivery systems market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type Of Molecule Delivered: Biologics; Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA); Deoxyribonucleic Acid (DNA); Proteins or Peptides; Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Development And Manufacturing Organizations (CDMOs); Hospitals And Clinics
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Non-Viral Drug Delivery Systems Market Characteristics
3. Non-Viral Drug Delivery Systems Market Trends And Strategies
4. Non-Viral Drug Delivery Systems Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Non-Viral Drug Delivery Systems Growth Analysis And Strategic Analysis Framework
5.1. Global Non-Viral Drug Delivery Systems PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Viral Drug Delivery Systems Market Growth Rate Analysis
5.4. Global Non-Viral Drug Delivery Systems Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Viral Drug Delivery Systems Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Viral Drug Delivery Systems Total Addressable Market (TAM)
6. Non-Viral Drug Delivery Systems Market Segmentation
6.1. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biologics
Small Molecules
6.2. Global Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ribonucleic Acid (RNA)
Deoxyribonucleic Acid (DNA)
Proteins Or Peptides
Antibodies
6.3. Global Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical And Biotechnology Companies
Academic And Research Institutes
Contract Development And Manufacturing Organizations (CDMOs)
Hospitals And Clinics
6.4. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peptides
Proteins
Monoclonal antibodies
RNA-based therapeutics
DNA-based therapies
6.5. Global Non-Viral Drug Delivery Systems Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapeutics
Anti-inflammatories
Antivirals
Antibiotics
Hormonal drugs
7. Non-Viral Drug Delivery Systems Market Regional And Country Analysis
7.1. Global Non-Viral Drug Delivery Systems Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Viral Drug Delivery Systems Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Non-Viral Drug Delivery Systems Market
8.1. Asia-Pacific Non-Viral Drug Delivery Systems Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Non-Viral Drug Delivery Systems Market
9.1. China Non-Viral Drug Delivery Systems Market Overview
9.2. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Non-Viral Drug Delivery Systems Market
10.1. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Non-Viral Drug Delivery Systems Market
11.1. Japan Non-Viral Drug Delivery Systems Market Overview
11.2. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Non-Viral Drug Delivery Systems Market
12.1. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Non-Viral Drug Delivery Systems Market
13.1. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Non-Viral Drug Delivery Systems Market
14.1. South Korea Non-Viral Drug Delivery Systems Market Overview
14.2. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Non-Viral Drug Delivery Systems Market
15.1. Western Europe Non-Viral Drug Delivery Systems Market Overview
15.2. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Non-Viral Drug Delivery Systems Market
16.1. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Non-Viral Drug Delivery Systems Market
17.1. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Non-Viral Drug Delivery Systems Market
18.1. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Non-Viral Drug Delivery Systems Market
19.1. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Non-Viral Drug Delivery Systems Market
20.1. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Non-Viral Drug Delivery Systems Market
21.1. Eastern Europe Non-Viral Drug Delivery Systems Market Overview
21.2. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Non-Viral Drug Delivery Systems Market
22.1. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Non-Viral Drug Delivery Systems Market
23.1. North America Non-Viral Drug Delivery Systems Market Overview
23.2. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Non-Viral Drug Delivery Systems Market
24.1. USA Non-Viral Drug Delivery Systems Market Overview
24.2. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Non-Viral Drug Delivery Systems Market
25.1. Canada Non-Viral Drug Delivery Systems Market Overview
25.2. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Non-Viral Drug Delivery Systems Market
26.1. South America Non-Viral Drug Delivery Systems Market Overview
26.2. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Non-Viral Drug Delivery Systems Market
27.1. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Non-Viral Drug Delivery Systems Market
28.1. Middle East Non-Viral Drug Delivery Systems Market Overview
28.2. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Non-Viral Drug Delivery Systems Market
29.1. Africa Non-Viral Drug Delivery Systems Market Overview
29.2. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Molecule Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Viral Drug Delivery Systems Market, Segmentation By Type Of Biologics Delivered, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Viral Drug Delivery Systems Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Non-Viral Drug Delivery Systems Market Competitive Landscape And Company Profiles
30.1. Non-Viral Drug Delivery Systems Market Competitive Landscape
30.2. Non-Viral Drug Delivery Systems Market Company Profiles
30.2.1. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Cytiva Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Arcturus Therapeutics Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. CureVac N.V. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. PolyPid Ltd Overview, Products and Services, Strategy and Financial Analysis
31. Non-Viral Drug Delivery Systems Market Other Major And Innovative Companies
31.1. Ethris GmbH
31.2. Entos Pharmaceuticals Inc.
31.3. Liquidia Technologies Inc.
31.4. ReCode Therapeutics Inc.
31.5. Enable Injections Inc.
31.6. GenEdit Inc.
31.7. N4 Pharma Plc
31.8. Hopewell Therapeutics Inc.
31.9. Tiba Biotech LLC
31.10. Vesigen Therapeutics Inc.
31.11. Carmine Therapeutics Inc.
31.12. Evox Therapeutics Ltd
31.13. InnoCore Pharmaceuticals BV
31.14. Nanomerics Ltd
31.15. DelSiTech Ltd
32. Global Non-Viral Drug Delivery Systems Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Non-Viral Drug Delivery Systems Market
34. Recent Developments In The Non-Viral Drug Delivery Systems Market
35. Non-Viral Drug Delivery Systems Market High Potential Countries, Segments and Strategies
35.1 Non-Viral Drug Delivery Systems Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Viral Drug Delivery Systems Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Viral Drug Delivery Systems Market In 2029 - Growth Strategies
